UA96412C2 - Применение комбинации вируса миксомы и рапамицина для лечения - Google Patents
Применение комбинации вируса миксомы и рапамицина для леченияInfo
- Publication number
- UA96412C2 UA96412C2 UAA200710934A UAA200710934A UA96412C2 UA 96412 C2 UA96412 C2 UA 96412C2 UA A200710934 A UAA200710934 A UA A200710934A UA A200710934 A UAA200710934 A UA A200710934A UA 96412 C2 UA96412 C2 UA 96412C2
- Authority
- UA
- Ukraine
- Prior art keywords
- rapamycin
- combination
- myxoma virus
- therapeutic treatment
- cells
- Prior art date
Links
- 241000700562 Myxoma virus Species 0.000 title abstract 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 229960002930 sirolimus Drugs 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005860 defense response to virus Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65881605P | 2005-03-07 | 2005-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA96412C2 true UA96412C2 (ru) | 2011-11-10 |
Family
ID=36952904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200710934A UA96412C2 (ru) | 2005-03-07 | 2006-03-06 | Применение комбинации вируса миксомы и рапамицина для лечения |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20090035276A1 (enExample) |
| EP (2) | EP1863906A4 (enExample) |
| JP (2) | JP2008531739A (enExample) |
| KR (1) | KR101479093B1 (enExample) |
| CN (2) | CN101137748B (enExample) |
| AU (1) | AU2006222500B2 (enExample) |
| CA (1) | CA2600675C (enExample) |
| DK (1) | DK2388315T3 (enExample) |
| IL (2) | IL185376A0 (enExample) |
| MX (1) | MX2007010962A (enExample) |
| NZ (2) | NZ560840A (enExample) |
| RU (1) | RU2461630C2 (enExample) |
| UA (1) | UA96412C2 (enExample) |
| WO (1) | WO2006094385A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ560840A (en) | 2005-03-07 | 2009-07-31 | Robarts Res Inst | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| KR20090014364A (ko) | 2006-06-01 | 2009-02-10 | 로바츠 리서치 인스티튜트 | 암 치료용 점액종 바이러스 변이종 |
| CN102124335B (zh) * | 2008-05-22 | 2014-07-30 | 第一药品株式会社 | 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性 |
| US20120100109A1 (en) * | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| DK2717887T3 (en) | 2011-06-09 | 2018-04-09 | Univ Florida | Methods for treating or preventing graft-versus-host disease |
| RU2695136C1 (ru) * | 2018-06-19 | 2019-07-22 | Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) | Онколитический способ терапии рака молочной железы. |
| SG11202101291VA (en) * | 2018-08-08 | 2021-03-30 | Univ Arizona State | Method for improved poxvirus yields |
| WO2020051248A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| WO2021046048A1 (en) | 2019-09-02 | 2021-03-11 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for improving oncolytic virus infection for nonpermissive cancers |
| KR20220078665A (ko) * | 2019-10-10 | 2022-06-10 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스 |
| AU2020361625A1 (en) * | 2019-10-10 | 2022-05-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus comprising immunomodulatory transgenes and uses thereof |
| WO2022139440A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 재조합 믹소마바이러스 및 이의 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| WO1997026904A1 (en) | 1996-01-25 | 1997-07-31 | Medical Research Council | Treatment of non-neuronal cancer using hsv mutant |
| WO1999004026A2 (en) | 1997-07-18 | 1999-01-28 | Chiron Corporation | Lentiviral vectors |
| US7041654B2 (en) * | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| IL135507A0 (en) | 1997-10-09 | 2001-05-20 | Pro Virus Inc | Treatment of neoplasms with viruses |
| US6264940B1 (en) * | 1998-08-05 | 2001-07-24 | The Research Foundation Of State University Of New York | Recombinant poliovirus for the treatment of cancer |
| CA2378567A1 (en) * | 1999-07-12 | 2001-01-18 | Viron Therapeutics, Inc. | Novel myxoma genes for immune modulation |
| CA2388807C (en) | 1999-11-12 | 2013-08-06 | Matthew C. Coffey | Viruses for the treatment of cellular proliferative disorders |
| AU2001261738A1 (en) * | 2000-05-17 | 2001-11-26 | London Health Sciences Centre | Compositions and methods for promoting immunosuppression |
| EP2762140B1 (en) * | 2001-02-19 | 2017-03-22 | Novartis AG | Treatment of solid brain tumours with a rapamycin derivative |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| CN1754002B (zh) * | 2002-08-12 | 2010-09-08 | 杰能斯有限公司 | 涉及痘病毒和癌的组合物及制备方法 |
| EP1601376B1 (en) * | 2003-03-07 | 2012-05-30 | Robarts Research Institute | Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection |
| PT1615640E (pt) * | 2003-04-22 | 2007-04-30 | Wyeth Corp | Combinações antineoplásticas |
| WO2005002607A2 (en) * | 2003-07-07 | 2005-01-13 | Oncolytics Biotech Inc. | Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac |
| CA2562904C (en) * | 2004-04-27 | 2013-07-02 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| NZ560840A (en) | 2005-03-07 | 2009-07-31 | Robarts Res Inst | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
-
2006
- 2006-03-06 NZ NZ560840A patent/NZ560840A/en unknown
- 2006-03-06 AU AU2006222500A patent/AU2006222500B2/en not_active Ceased
- 2006-03-06 CN CN2006800075336A patent/CN101137748B/zh not_active Expired - Fee Related
- 2006-03-06 KR KR1020077022872A patent/KR101479093B1/ko not_active Expired - Fee Related
- 2006-03-06 CA CA2600675A patent/CA2600675C/en not_active Expired - Fee Related
- 2006-03-06 US US11/908,076 patent/US20090035276A1/en not_active Abandoned
- 2006-03-06 UA UAA200710934A patent/UA96412C2/ru unknown
- 2006-03-06 RU RU2007137008/10A patent/RU2461630C2/ru not_active IP Right Cessation
- 2006-03-06 CN CN201110306752.7A patent/CN102357104B/zh not_active Expired - Fee Related
- 2006-03-06 MX MX2007010962A patent/MX2007010962A/es active IP Right Grant
- 2006-03-06 DK DK11174887.7T patent/DK2388315T3/da active
- 2006-03-06 JP JP2008500016A patent/JP2008531739A/ja active Pending
- 2006-03-06 WO PCT/CA2006/000315 patent/WO2006094385A1/en not_active Ceased
- 2006-03-06 NZ NZ577283A patent/NZ577283A/en not_active IP Right Cessation
- 2006-03-06 EP EP06705269A patent/EP1863906A4/en not_active Withdrawn
- 2006-03-06 EP EP11174887.7A patent/EP2388315B1/en not_active Not-in-force
-
2007
- 2007-08-20 IL IL185376A patent/IL185376A0/en unknown
-
2010
- 2010-08-04 US US12/850,599 patent/US20110195050A1/en not_active Abandoned
- 2010-09-07 IL IL208070A patent/IL208070A/en not_active IP Right Cessation
-
2012
- 2012-09-07 JP JP2012197457A patent/JP5674210B2/ja not_active Expired - Fee Related
- 2012-11-16 US US13/679,096 patent/US20130171106A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,737 patent/US9987315B2/en active Active
-
2018
- 2018-05-07 US US15/972,994 patent/US20180256656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2506085A (en) | Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV | |
| PL2155758T3 (pl) | Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka | |
| WO2009149179A3 (en) | Enhanced antiviral therapy methods and devices | |
| UA96412C2 (ru) | Применение комбинации вируса миксомы и рапамицина для лечения | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| WO2007044534A3 (en) | Vegf analogs and methods of use | |
| MX2010003916A (es) | Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). | |
| MX2011007195A (es) | Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih). | |
| WO2008127710A3 (en) | Methods for treating cancer resistant to erbb therapeutics | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| TW200833684A (en) | 5,6-ring annulated indole derivatives and methods of use thereof | |
| GEP20084520B (en) | Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases | |
| ATE363896T1 (de) | Gegen missbrauch gesicherte darreichungsform | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| AR059482A1 (es) | Uso de supresion inmune local para potenciar terapia viral oncolitica | |
| MX2010005107A (es) | Componente de silibinina para tratamiento contra hepatitis. | |
| MX2021008036A (es) | Bioplaguicidas para la enfermedad tizon tardio de la papa. | |
| MXPA05009526A (es) | Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica. | |
| WO2007076161A3 (en) | Compounds with therapeutic activity | |
| WO2007150008A3 (en) | Polypeptides from african swine virus as vaccines for preventive and therapeutic use | |
| WO2006078284A3 (en) | Methods and compositions related to antiviral therapy using algae and cyanobacteria | |
| SG155898A1 (en) | Treatment of diseases using nalmefene and its analogs | |
| WO2011091154A3 (en) | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth | |
| EP2021023A4 (en) | MYXOM VIRUS MUTANTS FOR CANCER TREATMENT | |
| HK1206985A1 (en) | Combination therapy of anti-mif antibodies and chemotherapeutics |